ALLMedicine™ Hypernatremia Center
Research & Reviews 520 results
https://doi.org/10.2215/CJN.0000000000000077
Clinical Journal of the American Society of Nephrology : ... Didsbury M, See EJ et. al.
Mar 9th, 2023 - In children with hypernatremia, current clinical guidelines recommend a reduction in serum sodium of 0.5 mmol/L per hour or less to avoid complications of cerebral edema. However, no large-scale studies have been conducted in the pediatric setting...
https://doi.org/10.1093/ndt/gfad041
Nephrology, Dialysis, Transplantation : Official Publicat... Pinter J, Genser B et. al.
Mar 3rd, 2023 - The five-year mortality rate for haemodialysis patients is over 50%. Acute and chronic disturbances in salt and fluid homeostasis contribute to poor survival and are established as individual mortality risk factors. However, their interaction in r...
https://doi.org/10.1016/j.jcrc.2023.154282
Journal of Critical Care; Rugg C, Woyke S et. al.
Mar 2nd, 2023 - To further analyse causes and effects of ICU-acquired hypernatremia. This retrospective, single-centre study, analysed 994 patients regarding ICU-acquired hypernatremia. Non-hypernatremic patients (n = 617) were compared to early-hypernatremic (on...
https://clinicaltrials.gov/ct2/show/NCT03384563
Feb 24th, 2023 - The anesthetic potency of an inhalational anesthetic is measured by the minimum alveolar concentration (MAC), or the dose required to suppress movement to a surgical stimulus in 50% of patients. This measure of potency may also be used to assess t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945675
Critical Care (London, England); Bollaert PE, Monnier A et. al.
Feb 23rd, 2023 - In critically ill patients, positive fluid balance is associated with excessive mortality. The POINCARE-2 trial aimed to assess the effectiveness of a fluid balance control strategy on mortality in critically ill patients. POINCARE-2 was a stepped...
Drugs 16 results see all →
Clinicaltrials.gov 45 results
https://clinicaltrials.gov/ct2/show/NCT03384563
Feb 24th, 2023 - The anesthetic potency of an inhalational anesthetic is measured by the minimum alveolar concentration (MAC), or the dose required to suppress movement to a surgical stimulus in 50% of patients. This measure of potency may also be used to assess t...
https://clinicaltrials.gov/ct2/show/NCT04987385
Feb 21st, 2023 - Hyponatremia (blood sodium <135 mmol/l) is the most frequent electrolyte and fluid disturbance with a prevalence up to 30% in hospitalized patients. The most common etiology of euvolemic hyponatremia is the syndrome of inappropriate antidiuresis (...
https://clinicaltrials.gov/ct2/show/NCT02914782
Nov 10th, 2022 - Critically ill patients need intravenous fluid therapy in order to correct or prevent problems with their fluid and/or electrolyte status and for renal protection. The decision for the optimal composition and amount of IV-fluids can be difficult a...
https://clinicaltrials.gov/ct2/show/NCT04949139
Aug 24th, 2022 - Hypernatremia is defined as serum sodium (sNa) levels above 145 mmol/L and is caused by abnormalities in water balance, mainly in children, elderly, and critically ill patients. It occurs in 3% of hospitalized patients and in 9% of critically ill ...
https://clinicaltrials.gov/ct2/show/NCT04781361
Aug 3rd, 2022 - Considering the physiological changes in fluid and electrolyte balance and providing proper support are one of the important aspects of neonatal intensive care. Maintenance intravenous fluids are designed to maintain homeostasis when a patient is ...
News 43 results
https://www.medscape.com/viewarticle/984087
Nov 15th, 2022 - Electrolyte abnormalities may serve as a precursor to a future eating disorder diagnosis, a finding that may help pinpoint candidates for screening. Researchers found that adolescents and adults with electrolyte abnormalities on routine outpatient...
https://www.medpagetoday.com/hematologyoncology/othercancers/100845
Sep 21st, 2022 - The FDA has approved sodium thiosulfate (Pedmark) as the first treatment for cisplatin-related ototoxicity in pediatric patients, Fennec Pharmaceuticals announced. The approved indication is to reduce the risk of ototoxicity associated with cispla...
https://www.onclive.com/view/fda-approves-pedmark-for-prevention-of-platinum-induced-ototoxicity-in-pediatric-solid-tumors
Sep 20th, 2022 - The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.1 The efficacy of the product was examined in pe...
https://www.onclive.com/view/real-world-data-underscore-importance-of-ntrk-gene-fusions-in-tumor-agnostic-therapies
Jul 6th, 2022 - The role of NTRK gene fusions across multiple cancer types have led investigators to confirm the marker in real-world data analyses.1 TRK fusion has become quite famous over the past few years, and we know this is a chromosomal rearrangement tha...
https://www.onclive.com/view/larotrectinib-continues-to-demonstrate-high-dcr-elicit-durable-responses-in-trk-fusion-cns-tumors
Jun 5th, 2022 - Larotrectinib (Vitrakvi) continued to produce rapid and durable responses, with a high disease control rate (DCR) and an acceptable toxicity profile in patients with TRK fusion–positive, primary central nervous system (CNS) tumors, according to lo...